An Alphabet Soup of 2026 Predictions: GLP-1s, ICH, GCP, CAR-T, AI & More
Article
Clinical
著者について
Darcy Grabenstein
Director of Content Strategy and Thought Leadership | Citeline
Darcy is the Director of Content Strategy and Thought Leadership for Citeline. A journalist by training, she has more than 30 years of experience in marketing, advertising, and public relations.
Successful recruitment doesn't start once the study starts. It begins at protocol design/site selection.
FAQ
How will patient recruitment evolve in 2026?
Recruitment will increasingly leverage AI and real-world data (RWD) for comprehensive patient matching, including tokenization to locate hard-to-find patients.
How will regulatory changes impact clinical trials in 2026?
The updated ICH GCP E6(R3) guideline emphasizes risk-proportionate, data-driven, tech-enabled trials with strong governance. Additionally, the UK Medicines for Human Use (Clinical Trials) Amendment Regulations 2025 will take effect in April 2026, reinforcing ethical frameworks and transparency requirements. ISRCTN may become the preferred registry for international clinical trials.
What role will AI play in clinical development?
AI will reshape protocol design, patient recruitment, and trial optimization. Formal AI governance and cross-functional data/AI teams will become standard, ensuring accountability and compliance with regulatory expectations.
